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INTRODUCTION
Retinoids are lipophilic vitamin A derivatives that have an important role 
throughout life, since they are essential in normal embryo development 
and in the maintenance of physiological processes such as reproduction, 
vision, immunomodulation, and tissue repair. At a cellular level, they 
present pro-differentiating, anti-proliferative, pro-apoptotic, and anti-
oxidant effects. These characteristics make them attractive potential 
chemopreventive and chemotherapeutic agents for cancer’s therapy.  
The aim of this study is to unravel the mechanisms of action of retinoids 
in normal cells and in one of the most lethal cancers of childhood, 
neuroblastoma.  
METHODS 
The main source of information was PubMed database. A first search of 
reviews about retinoids and “retinoids AND neuroblastoma” was followed 
by a search of those original articles which seemed more relevant.   
RESULTS 
General mechanisms of action of retinoids 
ATRA (all-trans retinoic acid), 13-cis-RA and 9-cis-RA are natural retinoids 
that have both genomic and nongenomic effects:
 
• Genomic effects: by binding to two nuclear receptors that act mostly 
as heterodimers, RAR (retinoic acid receptor)/RXR (retinoid x receptor), 
retinoids induce the transcription of their target genes. The interaction 
ligand-receptor leads to the recruitment of chromatin modifiers that 
decondense the chromatin of the promoter region of these genes, the 
called RARE (RA response elements) region. Consequently, 
transcription is activated. When there are no ligands, condensation of 
chromatin in RARE occurs, turning off the transcription. (Figure 1). 
 
• RA target genes: important role in controlling cell 
proliferation, differentiation and apoptosis. MYC, FOXA1, 
GATA3, and HOX genes, among many others. 
 
• Nongenomic effects: activation of several kinases cascades, such as 
p38MAPK/MSK1 and ERK/MAPK pathways.  
 
Neuroblastoma (NB): 
• Most common extracranial solid malignant tumor in childhood  
• Cause of 15% of cancer-related deaths in children2 
• Undifferentiated neuroectodermal cells à sympathetic nervous system affected 
• High – risk NB:  
o Most of them, amplification of MYCN oncogene 
o Long – term survival rate without RA: <20%3 
o Long – term survival rate with RA: <40%3 
o Actual treatment: myeloablative chemotherapy + bone marrow 
transplantation + 160 mg/m2/day 13-cis-RA (maintenance therapy) 
Retinoids in neuroblastoma 
Effects of ATRA and 13-cis-RA in neuroblastoma cells: 
• Inhibition of proliferation: via decreasing MYCN levels (Figure 2) 
• Neuronal differentiation: via activating ERK1/2 pathway (Figure 3) 
• 13-cis-RA less toxic and more effective than ATRA à 13-cis-RA in NB treatment 
 
Figure 1. General genomic mechanisms of retinoids1 
Figure 3. Stimulation of neuronal differentiation by RA 
Acquisition of drug resistance: 
• NB cells eventually develop resistance to 13-cis-RA (Figure 4). 
• Alternative: N-(4-hydroxyphenyl)-retinamide (fenretinide or 4-HPR) (Table 1) 
Retinoids act as anti-proliferative agents in 
neuroblastoma cells by decreasing the amount of the 
MYCN, an oncogene which is frequently amplified in 
high-risk neuroblastoma. By a nongenomic 
mechanism, they also stimulate neuronal 
differentiation. Thus, retinoids seem promising 
chemotherapeutic agents against this type of cancer.  
Although the long-term survival is still low, the 
incorporation of natural retinoids as maintenance 
therapy has supposed a step forward in the fight 
against high-risk neuroblastoma and the good results 
of the synthetic retinoid fenretinide are encouraging. 
CONCLUSION Table 1. Characteristics and 
mechanisms of action of 
fenretinide 
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Figure 2. Inhibition of NB cells proliferation by RA 
Figure 4. Mechanisms of drug-resistance development 
